more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$50.14 USD

-2.32 (-4.42%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

Top 18% (45 out of 250)

Industry: Medical Info Systems

View All Zacks #1 Ranked Stocks

Zacks News

Why Is Omnicell (OMCL) Up 4.8% Since Last Earnings Report?

by Zacks Equity Research Published on May 25,2019

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

OMCLNegative Net Change

Will Omnicell (OMCL) Gain on Rising Earnings Estimates?

by Zacks Equity Research Published on May 15,2019

Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

OMCLNegative Net Change

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Sweta Killa Published on May 09,2019

Sector ETF report for PSCH

NXGN vs. OMCL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research Published on April 29,2019

NXGN vs. OMCL: Which Stock Is the Better Value Option?

Omnicell (OMCL) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research Published on April 26,2019

Omnicell (OMCL) gains from solid segmental contributions in Q1; margins expand.

Omnicell (OMCL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

by Zacks Equity Research Published on April 18,2019

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OMCLNegative Net Change

Omnicell's Global Expansion on Track, Stiff Competition Ails

by Zacks Equity Research Published on March 18,2019

Although Omnicell (OMCL) is steadily expanding in the Middle East and South African belts, it sees a greater uptake of technologies across other regions of the world.

medical

Omnicell (OMCL) Up 27.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research Published on March 09,2019

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

OMCLNegative Net Change

Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research Published on February 08,2019

Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.

medical

Omnicell (OMCL) Q4 Earnings Surpass Estimates

by Zacks Equity Research Published on February 07,2019

Omnicell (OMCL) delivered earnings and revenue surprises of 4.48% and -1.35%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

OMCLNegative Net Change

Omnicell Solid on Geographic Expansion Amid Stiff Competition

by Zacks Equity Research Published on February 04,2019

Omnicell (OMCL) gains from expanding into new markets. Stiff rivalry is a concern.

medical

Omnicell (OMCL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research Published on January 31,2019

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OMCLNegative Net Change

Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark

by Zacks Equity Research Published on January 30,2019

Illumina's (ILMN) Q4 figures show a sturdy uptick in sequencing consumable revenues.

Here's Why You Should Snap Up Abbott (ABT) Stock Right Now

by Zacks Equity Research Published on January 29,2019

We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.

medical

Thermo Fisher (TMO) Down on Business Divestment Declaration

by Zacks Equity Research Published on January 29,2019

Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.

medical

CVS Health's PBM Pharmacy Platform to Ride on Walmart Deal

by Zacks Equity Research Published on January 22,2019

Per the terms of the deal between CVS Health (CVS) and Walmart, the latter will continue to take part in the CVS Caremark PBM commercial and Managed Medicaid retail pharmacy networks.